Ciprofloxacin, 500 mg 10 pcs

A broad-spectrum antimicrobial agent of the group of fluoroquinolones. It has a bactericidal effect. Inhibits DNA-GiRase and inhibits the synthesis of bacterial DNA.

Highly active against most gram-negative bacteria: Pseudomonas aeruginosa, Haemophilus influenzae, Escherichia coli, Shigella spp., Salmonella spp., Neisseria meningitidis, Neisseria gonorrhoeae.

Active against Staphylococcus spp. (including penicillinase producing and non-producing strains, methicillin-resistant strains), some strains of Enterococcus spp., Campylobacter spp., Legionella spp., Mycoplasma spp., Chlamydia spp., Mycobacterium spp.

Ciprofloxacin is active against bacteria producing β-lactamases.

Ureaplasma urealyticum, Clostridium difficile, Nocardia asteroides are resistant to ciprofloxacin. Its action against Treponema pallidum has not been studied sufficiently.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to ciprofloxacin, incl. diseases of the respiratory tract, abdominal cavity and pelvic organs, bones, joints, skin; septicemia; severe infections of the ENT organs. Treatment of postoperative infections. Prevention and treatment of infections in patients with reduced immunity.

For local use: acute and subacute conjunctivitis, blepharoconjunctivitis, blepharitis, bacterial corneal ulcers, keratitis, keratoconjunctivitis, chronic dacryocystitis, meibomitis. Infectious eye lesions after injury or foreign bodies. Preoperative prophylaxis in ophthalmic surgery.

Pharmacological effect

Broad-spectrum antimicrobial agent of the fluoroquinolone group. Has a bactericidal effect. Suppresses DNA gyrase and inhibits bacterial DNA synthesis.

Highly active against most gram-negative bacteria: Pseudomonas aeruginosa, Haemophilus influenzae, Escherichia coli, Shigella spp., Salmonella spp., Neisseria meningitidis, Neisseria gonorrhoeae.

Active against Staphylococcus spp. (including strains that produce and do not produce penicillinase, methicillin-resistant strains), some strains of Enterococcus spp., Campylobacter spp., Legionella spp., Mycoplasma spp., Chlamydia spp., Mycobacterium spp.

Ciprofloxacin is active against bacteria that produce β-lactamases.

Ureaplasma urealyticum, Clostridium difficile, and Nocardia asteroides are resistant to ciprofloxacin. The effect against Treponema pallidum has not been sufficiently studied.

Special instructions

In patients with impaired renal function, dosage regimen adjustment is required. Use with caution in elderly patients, with atherosclerosis of cerebral vessels, cerebrovascular accidents, epilepsy, and convulsive syndrome of unknown etiology.

During treatment, patients should receive sufficient fluids.

In case of persistent diarrhea, ciprofloxacin should be discontinued.

With simultaneous intravenous administration of ciprofloxacin and barbiturates, monitoring of heart rate, blood pressure, and ECG is necessary. During treatment, it is necessary to control the concentration of urea, creatinine, and liver transaminases in the blood.

During treatment, a decrease in reactivity is possible (especially when used simultaneously with alcohol).

Ciprofloxacin should not be administered subconjunctivally or directly into the anterior chamber of the eye.

Active ingredient

Ciprofloxacin

Composition

For one tablet:

Active ingredient:

ciprofloxacin hydrochloride – 582.20 mg (in terms of ciprofloxacin – 500.00 mg);

Excipients of the tablet core:

corn starch – 7.20 mg;

partially pregelatinized corn starch (Starch 1500) – 60.00 mg;

microcrystalline cellulose – 86.20 mg;

crospovidone (kollidon CL) – 15.40 mg;

magnesium stearate – 7.60 mg;

lactose monohydrate – 26.60 m;

talc – 14.80 mg.

Film coating excipients:

hypromellose – 11.56 mg;

polyethylene glycol 6000 – 4.88 mg;

titanium dioxide – 1.78 mg;

polysorbate 80 – 1.78 mg.

Contraindications

Pregnancy, lactation (breastfeeding), childhood and adolescence under 18 years of age, hypersensitivity to ciprofloxacin and other quinolone drugs.

Side Effects

From the digestive system: nausea, vomiting, diarrhea, abdominal pain, increased activity of liver transaminases, alkaline phosphatase, LDH, bilirubin, pseudomembranous colitis.

From the central nervous system: headache, dizziness, feeling of fatigue, sleep disorders, nightmares, hallucinations, fainting, visual disturbances.

From the urinary system: crystalluria, glomerulonephritis, dysuria, polyuria, albuminuria, hematuria, transient increase in serum creatinine.

From the hematopoietic system: eosinophilia, leukopenia, neutropenia, change in platelet count.

From the cardiovascular system: tachycardia, heart rhythm disturbances, arterial hypotension.

Allergic reactions: skin itching, urticaria, Quincke’s edema, Stevens-Johnson syndrome, arthralgia.

Adverse reactions associated with chemotherapy: candidiasis.

Local reactions: pain, phlebitis (with intravenous administration). When using eye drops, in some cases, mild soreness and hyperemia of the conjunctiva are possible.

Other: vasculitis.

Interaction

With simultaneous use of ciprofloxacin with didanosine, the absorption of ciprofloxacin is reduced due to the formation of ciprofloxacin complexes with aluminum and magnesium buffers contained in didanosine.

When used simultaneously with warfarin, the risk of bleeding increases.

With the simultaneous use of ciprofloxacin and theophylline, it is possible to increase the concentration of theophylline in the blood plasma, increase T1/2 of theophylline, which leads to an increased risk of developing toxic effects associated with theophylline.

Simultaneous use of antacids, as well as drugs containing aluminum, zinc, iron or magnesium ions, can cause a decrease in the absorption of ciprofloxacin, so the interval between the administration of these drugs should be at least 4 hours.

Recommendations for use

Individual. Orally – 250-750 mg 2 times a day. The duration of treatment is from 7-10 days to 4 weeks.

For intravenous administration, a single dose is 200-400 mg, the frequency of administration is 2 times a day; Duration of treatment is 1-2 weeks, or more if necessary. It can be administered intravenously as a stream, but drip administration over 30 minutes is more preferable.

When applied topically, instill 1-2 drops into the lower conjunctival sac of the affected eye every 1-4 hours. After the condition improves, the intervals between instillations can be increased.

The maximum daily dose for adults when taken orally is 1.5 g.

Manufacturer

Sintez, Russia